Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is poised for success with its EP-104GI, as it targets a significant unmet medical need for EoE and esophageal strictures. Its Diffusphere technology sets it apart from existing steroids, providing improved efficacy, durability, and reduced treatment burden. While risks exist, the company's current market cap suggests a high probability of success, making it an attractive investment opportunity. As of 2036, based on an 11.0% WACC and 12.0x exit multiple, the net present value of EP-104GI is ~$500M, with an 85% probability of success factored in.

Bears say

Eupraxia Pharmaceuticals is facing significant challenges in terms of gaining widespread adoption and generating profits for its EP-104GI drug due to the differing endpoints in benign strictures when compared to its current EoE program. Additionally, the use of EP-104GI in strictures would likely require far fewer injections and possibly lower pricing, posing a risk to the company's revenue potential. While the data on EP-104GI's efficacy and safety look promising, the success of the upcoming randomized Phase 2b readout will be crucial in determining the drug's long-term viability and market potential.

EPRX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 4 analysts, EPRX has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.